Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

10.75USD
4:02pm EDT
Change (% chg)

$-0.11 (-1.01%)
Prev Close
$10.86
Open
$10.79
Day's High
$10.94
Day's Low
$10.70
Volume
2,136,707
Avg. Vol
3,048,135
52-wk High
$38.48
52-wk Low
$10.35

Latest Key Developments (Source: Significant Developments)

Bausch + Lomb Canada launches bepreve 1.5 pct w/v for allergic conjunctivitis
Wednesday, 22 Mar 2017 07:30am EDT 

Valeant Pharmaceuticals International Inc :Bausch + Lomb - Bausch + Lomb Canada launches bepreve (bepotastine besilate ophthalmic solution) 1.5 pct w/v for allergic conjunctivitis.  Full Article

Bausch + Lomb and Nicox announce PDUFA date for novel glaucoma candidate latanoprostene bunod
Monday, 20 Mar 2017 05:00pm EDT 

Nicox Sa : Bausch + lomb and nicox announce pdufa date for novel glaucoma candidate latanoprostene bunod .Valeant - fda has set a pdufa date of august 24, 2017 for its decision on new drug application (nda) for latanoprostene bunod ophthalmic solution.  Full Article

ValuAct reports open market purchse of 500,000 shares of Valeant Pharma
Thursday, 16 Mar 2017 05:47pm EDT 

Valeant Pharmaceuticals International Inc : ValueAct Holdings LP reports open market purchse of 500,000 shares of valeant pharmaceuticals at average price of $10.88/share on March 14 - SEC filing .ValueAct Holdings LP reports open market purchse of 2.5 million shares of Valeant Pharmaceuticals at average price of $10.81/share on March 14.  Full Article

Valueact Holdings reports 5.2 pct stake in Valeant Pharma
Thursday, 16 Mar 2017 05:29pm EDT 

Valeant Pharmaceuticals International Inc : Valueact Holdings L.P. Reports 5.2 percent stake in valeant pharma, as of march 14, 2017 . Valueact Holdings-have had, intend to continue to have discussions with officers & directors of valeant to discuss ways to "enhance shareholder value" . Valueact Holdings l.p. Acquired securities of valeant based on belief that securities were "undervalued", represented "attractive investment opportunity" . Valueact Holdings says topics of conversations with valeant will include management, board composition, operations, capital allocation, among others .Valueact Holdings says topics of conversations with valeant will also include financial condition, mergers and acquisitions strategy, overall business strategy.  Full Article

Valeant Pharma CFO Paul Herendeen reports open market purchase of co's shares
Thursday, 16 Mar 2017 05:13pm EDT 

Valeant Pharmaceuticals International Inc :Valeant pharmaceuticals-cfo paul herendeen reports open market purchase of 24,000 shares of co's common stock at average price of $10.72per share on march 14.  Full Article

Valeant's Bausch + Lomb reports introduction of Biotrue Oneday
Wednesday, 15 Mar 2017 07:00am EDT 

Valeant Pharmaceuticals International Inc :Valeant - subsidiary Bausch + Lomb, announced introduction of Biotrue Oneday for astigmatism daily disposable contact lenses.  Full Article

Pershing Square Capital Management says in regulatory filing it dissolved stake in Valeant as of March 13, 2017
Tuesday, 14 Mar 2017 04:36pm EDT 

Pershing Square Capital Management LP:Pershing Square Capital Management LP says in regulatory filing it dissolved stake in Valeant Pharma as of March 13, 2017.  Full Article

Ackman sold 27.2 million Valeant shares at $11- CNBC
Monday, 13 Mar 2017 04:28pm EDT 

: Ackman out of Valeant; he sold 27.2 million shares at $11 & believes he'll be stepping off Co.'s board - CNBC, citing sources Further company coverage: [VRX.TO] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Valeant receives lender consent for refinancing, amendment of credit agreement
Friday, 10 Mar 2017 04:30pm EST 

Valeant Pharmaceuticals International Inc : Valeant receives lender consent for refinancing and amendment of credit agreement . Valeant - obtained requisite lender approval for previously announced amendment of company's existing credit agreement . Valeant - credit agreement amendment is expected to become effective concurrently with funding of new term b loans on or about March 21, 2017 .Valeant - obtained requisite lender approval for amendment of existing credit agreement to facilitate borrowing of new term b loans that mature in 2022.  Full Article

Valeant says priced offering of $1.25 bln aggregate principal amount of 6.50% senior secured notes due 2022
Friday, 10 Mar 2017 06:30am EST 

Valeant Pharmaceuticals International Inc : Valeant - priced its previously announced offering of $1.25 billion aggregate principal amount of 6.50% senior secured notes due 2022 . Valeant - priced its previously announced offering of $2 billion aggregate principal amount of 7.00% senior secured notes due 2024 . Valeant announces pricing and upsize of private offering of senior secured notes . Valeant - aggregate size of offering reflects an increase of $750 million from previously announced offering size .Valeant -anticipates will pay down $350 million of revolving credit facility borrowings under credit facilities with proceeds of offering, cash on hand.  Full Article

More From Around the Web